about
Drug repurposing: a systematic approach to evaluate candidate oral neuroprotective interventions for secondary progressive multiple sclerosisProcedural confidence in hospital based practitioners: implications for the training and practice of doctors at all grades.The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessmentsAutologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.Hypothermic Preconditioning of Human Cortical Neurons Requires Proteostatic PrimingHypothermic Preconditioning Reverses Tau Ontogenesis in Human Cortical Neurons and is Mimicked by Protein Phosphatase 2A Inhibition.Development of a high-resolution fat and CSF-suppressed optic nerve DTI protocol at 3T: application in multiple sclerosis.Patterns of cognitive dysfunction in progressive MS.Genetic epidemiology of motor neuron disease-associated variants in the Scottish population.Stem cells as a resource for regenerative neurology.Mesenchymal stromal cell transplantation modulates neuroinflammatory milieu in amyotrophic lateral sclerosis.Psychometric properties of the PHQ-9 depression scale in people with multiple sclerosis: A systematic reviewMultiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiplPsychometric properties of the PHQ-9 depression scale in people with multiple sclerosis: a systematic reviewThe neuromuscular emergency consultPATTERNS OF COGNITIVE DYSFUNCTION IN PROGRESSIVE MULTIPLE SCLEROSISVerbal fluency as a rapid screening test for cognitive impairment in progressive multiple sclerosis: Figure 1Lipid Profile Components and Risk of Ischemic Stroke: A Role for the Pleiotropic Effects of Statins
P50
Q28545984-32C5B072-F2A3-408B-920D-6DE4651B0CF5Q33399271-22D2194F-9A71-4892-BD2F-D650212255EEQ34686955-6EC94700-FAFB-40D0-B1E0-D98654161361Q35757641-2D6D5A9A-8554-4286-AFF7-710D2AC1183AQ35947718-603BA43C-86F7-4DEF-92A5-5D28DECBF52FQ36538815-9C1D8689-3F32-4BF3-9B8B-CEB788AA01E7Q37267155-2D8F8070-52B2-41A3-B802-D5233A46898FQ37561350-F255C1F6-771A-48E8-B1F6-296A754993E6Q37635851-6BC47F3B-DB87-4C71-A099-95CF6A9E443AQ37829160-0C31A514-78C4-48B5-A7F7-EC8DECEDA96AQ48674044-D416EECD-CD1C-465F-90BF-B79E185F19C9Q64256084-ABB09819-5A82-46FF-8AE2-736B8418A7F4Q64450175-0CB2A37F-6B2B-458F-8849-9268AF86A1A4Q64450177-D7F23018-59C8-429B-8A4F-D00B863FA9B2Q64450180-8C2C2B28-46C5-46E0-8831-EF4D7DD09E9CQ64450182-8636C801-F99C-4FBE-A4DA-7D5BE84B3EADQ64450185-BF6B2417-49C2-4E1E-9E7E-F1947162928FQ64450188-707B01ED-4553-4969-943E-2FFDF4D33FDA
P50
description
researcher
@en
researcher
@en-gb
wetenschapper
@nl
հետազոտող
@hy
name
Peter Connick
@ast
Peter Connick
@en
Peter Connick
@en-gb
Peter Connick
@es
Peter Connick
@nl
Peter Connick
@sl
type
label
Peter Connick
@ast
Peter Connick
@en
Peter Connick
@en-gb
Peter Connick
@es
Peter Connick
@nl
Peter Connick
@sl
prefLabel
Peter Connick
@ast
Peter Connick
@en
Peter Connick
@en-gb
Peter Connick
@es
Peter Connick
@nl
Peter Connick
@sl
P106
P21
P31
P496
0000-0002-3892-8037